acquisitions

Three consumer staples companies—Marzetti, Sanfilippo, and Ingles Markets—offer reliable dividend income with dominant market positions and strategic growth initiatives for 2026.

Nestlé sells Blue Bottle; Netflix acquires AI startup InterPositive; Six Flags divests parks; Eddie Bauer bankruptcy auction fails; Cumulus Media files Chapter 11 restructuring.

Boston Scientific positioned to capitalize on global aging through AFib, chronic pain, and Parkinson's treatments; recent acquisitions boost stroke capabilities.

Niagen Bioscience doubled annual profits with $129.4M in sales and 30% revenue growth. CEO signals acquisition hunt and GLP-1-style expansion despite modest 2026 guidance.

BigBear.ai stock hits long-term lows in 2025, but resolved debt and dilution issues plus strategic acquisitions attract institutional buying.

GPGI shares jump 70% as Progeny 3 expands $24.5M stake; rebranded company pursues disciplined acquisitions across metal cards and industrial manufacturing.

Cybersecurity market expanding to $500B by 2030 as AI adoption accelerates. Palo Alto Networks positioned for growth despite recent stock decline.

IonQ stock jumped 21% on Q4 results beating guidance by 55% and robust 2026 revenue outlook, though the company remains unprofitable.

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.

Lowe's stock fell 5.5% despite beating quarterly earnings, as cautious 2026 guidance signaling weak housing market demand disappointed investors seeking stronger growth forecasts.

ZenaTech wins 2026 award for aggressive expansion, completing 20 acquisitions in 2025 to consolidate the drone-as-service market and build recurring revenue streams.

Republic Services plans $1B in acquisitions despite weak cash flow and modest 2026 growth guidance, raising investor concerns about financial flexibility.

Roper Technologies' board approved a $0.91 quarterly dividend per share, payable April 22, 2026, reflecting the company's commitment to shareholder returns and disciplined capital allocation.

InterCure reported 11% revenue growth to NIS 265M in 2025, maintaining profitability for the twelfth consecutive half-year. Growth driven by German market expansion and strategic acquisitions.

Energy Transfer generated record $8.2B in distributable cash flow, far exceeding its 7.2% dividend requirements. The midstream company projects 9-12% EBITDA growth in 2026.

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.